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OBSERVATIONAL STUDY

Multicenter Retrospective Review of Ketamine
Use in the ICU
IMPORTANCE: The response of ICU patients to continuously infused ketamine
when it is used for analgesia and/or sedation remains poorly established.
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OBJECTIVES: To describe continuous infusion (CI) ketamine use in critically ill
patients, including indications, dose and duration, adverse effects, patient outcomes, time in goal pain/sedation score range, exposure to analgesics/sedatives,
and delirium.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, retrospective, observational study from twenty-five diverse institutions in the United States. Patients
receiving CI ketamine between January 2014 and December 2017.
MAIN OUTCOMES AND MEASURES: Chart review evaluating institutional
and patient demographics, ketamine indication, dose, administration, and adverse
effects. Pain/sedation scores, cumulative doses of sedatives and analgesics, and
delirium screenings in the 24 hours prior to ketamine were compared with those
at 0–24 hours and 25–48 hours after.
RESULTS: A total of 390 patients were included (median age, 54.5 yr; interquartile range, 39–65 yr; 61% males). Primary ICU types were medical
(35.3%), surgical (23.3%), and trauma (17.7%). Most common indications
were analgesia/sedation (n = 357, 91.5%). Starting doses were 0.2 mg/kg/hr
(0.1–0.5 mg/kg/hr) and continued for 1.6 days (0.6–2.9 d). Hemodynamics in
the first 4 hours after ketamine were variable (hypertension 24.0%, hypotension 23.5%, tachycardia 19.5%, bradycardia 2.3%); other adverse effects were
minimal. Compared with 24 hours prior, there was a significant increase in proportion of time spent within goal pain score after ketamine initiation (24 hr prior:
68.9% [66.7–72.6%], 0–24 hr: 78.6% [74.3–82.5%], 25–48 hr: 80.3% [74.6–
84.3%]; p < 0.001) and time spent within goal sedation score (24 hr prior: 57.1%
[52.5–60.0%], 0–24 hr: 64.1% [60.7–67.2%], 25–48 hr: 68.9% [65.5–79.5%];
p < 0.001). There was also a significant reduction in IV morphine (mg) equivalents (24 hr prior: 120 [25–400], 0–24 hr: 118 [10–363], 25–48 hr: 80 [5–328];
p < 0.005), midazolam (mg) equivalents (24 hr prior: 11 [4–67], 0–24 hr: 6 [0–68],
25–48 hr: 3 [0–57]; p < 0.001), propofol (mg) (24 hr prior: 942 [223–4,018],
0–24 hr: 160 [0–2,776], 25–48 hr: 0 [0–1,859]; p < 0.001), and dexmedetomidine (µg) (24 hr prior: 1,025 [276–1,925], 0–24 hr: 285 [0–1,283], 25–48 hr: 0
[0–826]; p < 0.001). There was no difference in proportion of time spent positive
for delirium (24 hr prior: 43.0% [17.0–47.0%], 0–24 hr: 39.5% [27.0–43.8%],
25–48 hr: 0% [0–43.7%]; p = 0.233). Limitations to these data include lack of a
comparator group, potential for confounders and selection bias, and varying pain
and sedation practices that may have changed since completion of the study.
CONCLUSIONS AND RELEVANCE: There is variability in the use of CI ketamine. Hemodynamic instability was the most common adverse effect. In the 48
hours after ketamine initiation compared with the 24 hours prior, proportion of
time spent in goal pain/sedation score range increased and exposure to other
analgesics/sedatives decreased.
KEY WORDS: analgesia; delirium; drug-related side effects and adverse
reactions; hypnotics and sedatives; intensive care units; ketamine
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etamine is a rapid-acting anesthetic agent
originally developed in the 1960s for induction of anesthesia. Antagonism of the
N-methyl-D-aspartate receptor produces analgesia
at low doses (≤ 0.5 mg/kg/hr) and amnesia and unresponsiveness without suppressing spontaneous respirations or involuntary limb movement at higher doses
(≥ 1 mg/kg/hr) (1). Ketamine also possesses activity
at opioid, monoaminergic, cholinergic, nicotinic, and
muscarinic receptors, which may result in increased
blood pressure, heart rate (HR), and cardiac output,
bronchodilation, and antidepressant and anti-inflammatory effects (1–3). This unique pharmacology combined with a relatively low acquisition cost has led to
increased use for a wide variety of off-label indications
in the ICU (4–12).
Unfortunately, there is limited research available
to guide use of continuous infusion (CI) ketamine
in the ICU. The 2018 Clinical Practice Guidelines for
the Prevention and Management of Pain, Agitation/
Sedation, Delirium, Immobility, and Sleep Disruption
in Adult Patients in the ICU suggest using low-dose ketamine (0.5 mg/kg × 1 followed by a 1–2 µg/kg/min CI)
as an adjunct to opioid therapy when seeking to reduce opioid consumption in postsurgical adults admitted to the ICU (conditional recommendation, very low
quality of evidence) (13). They do not address use of
ketamine as a sedative agent; therefore, specific recommendations related to its prescribing and monitoring
remain absent (13). These guidelines do recommend
to optimize analgesia first with a multimodal analgesic
approach, followed by light sedation using either propofol or dexmedetomidine (13). However, critically
ill patients often have barriers to implementing these
strategies, including contraindications to nonopioid
analgesics, dose-limiting adverse effects, and/or failure
of conventional therapy particularly when deep sedation is necessary. Ketamine may be an ideal benzodiazepine sparing option in these situations; however,
its comparative effects on delirium and other risks are
unknown.
This study sought to describe use of CI ketamine in
critically ill patients, including indications, dose and
duration, adverse effects, patient outcomes, proportion
of time in goal pain/sedation score range, exposure to
analgesics/sedatives, and delirium. We hypothesized
after CI ketamine initiation, proportion of time spent
in goal pain and sedation score range would increase,
2     www.ccejournal.org

cumulative exposure to other analgesic and sedative
agents would decrease, and proportion of time spent
positive for delirium would decrease.

MATERIALS AND METHODS
Study Setting and Design
This was a multicenter, retrospective, observational
study of adult patients who received CI ketamine
while admitted to an ICU between January 2014 and
December 2017. The primary objective was to describe CI ketamine indications, dose, and duration of
therapy. Secondary objectives were to determine the
occurrence rate of adverse effects, proportion of time
spent in goal pain and sedation score range, cumulative doses of analgesics and sedatives, proportion of
time spent positive for delirium, and describe patient
outcomes.
The study was designed and executed by members
of the Ketamine-ICU study group, who were recruited
through the American College of Clinical Pharmacy
(ACCP) Practice-Based Research Network (now the
ACCP Foundation). Additional sites were recruited
to participate from the ACCP Critical Care Practice
and Research Network via electronic mail and targeted contact by investigators. All study sites received
approval for conduct of this study with waivers of informed consent from their Institutional Review Boards
(IRBs). Each site was listed within the IRB approval
from University of Rochester Office for Human Subject
Protection (STUDY00001686), which functioned as
the coordinating site. The guidelines for reporting
observational studies with the Strengthening the
Reporting of Observational Studies in Epidemiology
checklist was used to strengthen the reporting of our
findings.
Patient Population
Patients were included if greater than or equal to 18
years old and received CI ketamine for any duration of
time while in an ICU during the study time frame and
excluded only if transferred in from an outside hospital already receiving CI ketamine. Due to the large
amount of data points collected, participating sites
were instructed to collect data on as many patients as
they could during the data collection timeframe starting with the most recent patients first.
February 2022 • Volume 4 • Number 2
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Data Collection and Outcomes
Standardized data collection was performed in a secure Research Electronic Data Capture (REDCap) database. The data collection tool was developed, tested,
and refined for ease of use and standardization by the
Ketamine-ICU study group. Prior to the study start
date, all sites independently reviewed and tested the
REDCap tool, reviewed the data dictionary, and participated in a conference call hosted by the coordinating site.
Data collection included both institutional and patient demographics (Methods, Supplemental Digital
Content, http://links.lww.com/CCX/A910). Data
collected for CI ketamine included initial ketamine
indication, bolus doses and infusion rate, titration
instructions, CI concentration, daily minimum and
maximum infusion rates, cumulative doses up to day
7 of therapy, and total duration of therapy.
Data points collected to evaluate for adverse effects
included the presence of hypertension, hypotension,
tachycardia, bradycardia, or any cardiac abnormalities in the first 4, 24, and 48 hours after CI ketamine
initiation. Systolic blood pressure (SBP), mean arterial pressure (MAP), and HR were compared in the 4
hours prior to and 4 hours after CI ketamine initiation.
These time frames were chosen to limit the potential for confounders but also describe hemodynamic
changes commonly seen during the first few days of
therapy. Additional adverse effects that could be doserelated or occur at any time point during therapy such
as seizures, hypertonia, hypersalivation, and emergence, allergic, and injection site reactions were collected during the first 7 days of CI ketamine or until
ketamine was discontinued, whichever occurred first.
Definitions of adverse effect endpoints can be found in
Supplemental Digital Content (Table S1, http://links.
lww.com/CCX/A910).
Data collected to describe CI ketamine analgesia
and sedation practices in patients receiving ketamine
for an analgesia or sedation indication included baseline oral/IV analgesic, sedative, and antipsychotic use
in the 24 hours prior to ketamine including epidural
use. Total cumulative doses of IV analgesics (opioids)
and sedatives (benzodiazepines, propofol, dexmedetomidine) given in the 24 hours prior to ketamine were
compared with cumulative doses given in the first 0–24
hours and 25–48 hours of the infusion. Cumulative
Critical Care Explorations

doses of opioids and benzodiazepines were converted to IV morphine equivalents in mg (fentanyl 100
µg = hydromorphone 1.5 mg = morphine 10 mg) and
midazolam equivalents in mg (lorazepam 1 mg = diazepam 5 mg = midazolam 2 mg), respectively (14, 15).
Antipsychotic use was collected in all patients during
the first 7 days of CI ketamine or until the infusion was
discontinued, whichever occurred first.
To determine the proportion of time spent in goal
pain/sedation score range, all pain and sedation
scores recorded in the 24 hours prior to CI ketamine
initiation were compared with those recorded in the
first 0–24 hours and 25–48 hours of the infusion for
those receiving CI ketamine for a pain or sedation
indication. Goal pain and sedation scores were determined by medical chart review and, if unknown,
goal pain scores were assumed to be equivalent to
scores indicating no pain to mild pain (Nonverbal
Pain Scale 0–3, Behavioral Pain Scale 3–5, Critical
Care Pain Observational Tool 0–2, Numerical Rating
Pain Scale 0–2, Multidimensional Objective Pain
Assessment Tool 1–3, Defense and Veterans Pain
Rating Scale of 0–2, Pain Assessment in Advanced
Dementia Scale 1–3, Wong-Baker Faces Pain Rating
Scale 0–2) and sedation scores were assumed to
be equivalent to scores indicating light sedation
(Richmond Agitation-Sedation Scale [RASS] –2 to 0
or Sedation Agitation Scale [SAS] 3–4). Similarly, to
determine the proportion of time spent positive for
delirium, all delirium screenings recorded in the 24
hours prior to CI ketamine initiation were compared
with those recorded in the first 0–24 hours and 25–48
hours of the infusion in all patients. The proportion
of delirium screenings positive for delirium were
collected for the first 7 days of the infusion or until
the infusion was discontinued, whichever occurred
first. To measure pain and sedation endpoints, the
scale used, the score, time the score was taken, and
whether the score was in the goal range were collected. Similarly, the delirium screening tool, positive or negative result, time the screening was taken,
and whether the patient was able to be screened for
delirium based on their level of consciousness (SAS
> 2, RASS > –2) were collected for the delirium
endpoints.
Patient outcomes evaluated in all patients were ICU
and hospital length of stay, 28-day ventilator-free days,
discharge disposition, and mortality.
www.ccejournal.org
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Statistical Analysis
Data were evaluated using SAS software (Version
[9.4], copyright © [2016]; SAS Institute, Cary, NC)
and SigmaPlot 14 software (Systat, San Jose, CA) and
reported using descriptive statistics with mean and
sd or median and interquartile range, as appropriate.
Continuous data were compared with Student’s t test,
Wilcoxon rank-sum test, one-way analysis of variance
(ANOVA), or Kruskal-Wallis test by ranks depending
on number of groups and data distribution. Beforeand-after data were compared with paired t tests,
signed rank-sum, or repeated measures ANOVA on
ranks. Differences in hemodynamics and cardiac
abnormalities were assessed using Cochran’s Q test.
Median values were used for comparison of integerbased scoring systems (e.g., SAS, RASS). As various
different pain and sedation scales were used between
institutions, collected values were categorized and
evaluated as proportion of time within goal based on
institution-specific or patient-specific goals at the time
of data collection.
Reported drug doses suspected to be erroneous (falling outside of three sds from the mean) were excluded
from the analysis given concerns for data entry error
suspected due to the varying dosing units observed in
practice. A sensitivity analysis was conducted to confirm that removal of these values did not change the
outcome. While the amount of data removed varied
due to different numbers of patients on each agent, less
than 2.5% of data points were removed overall.

RESULTS
Institution and Study Population Demographics
Twenty-five geographically diverse institutions were
included. Patient numbers by institution can be
found in Supplemental Digital Content (Table S2,
http://links.lww.com/CCX/A910). These were moderate to large institutions with most having clinical
practice guidelines for managing pain and agitation
(n = 18, 72%), however, very few included ketamine
(n = 5/18, 27.8%). Several institutions had separate
guidelines for ketamine use that included many indications in addition to pain/agitation (n = 17, 68%).
Further details on institution demographics, pain, agitation, and delirium assessment tools and ketamine
practices are available in Supplemental Digital Content
(Tables S3 and S4, http://links.lww.com/CCX/A910).
4     www.ccejournal.org

There were 390 adult patients evaluated with a median age of 54.5 years (39–65 yr) and majority were
male (61%). Most were located in an ICU at the time of
CI ketamine initiation (n = 362, 92.8%) and the primary
ICU types were medical (35.3%), surgical (23.3%),
and trauma (17.7%). Admitting diagnoses were variable but were mostly for trauma (23.8%), respiratory
failure (22.1%), postsurgical care (11.5%), and shock
(10.5%). The study population was reflective of a moderate to severely ill patient cohort with a median Acute
Physiology and Chronic Health Evaluation II score of
21 (14–27), 310 (79%) on mechanical ventilation, 132
(33.9%) on vasopressor therapy, and 36 (9.2%) on CI
neuromuscular blocking agents. Additional patient
demographics and admitting diagnoses are available in
Table 1 and Supplemental Digital Content (Tables S5
and S6, http://links.lww.com/CCX/A910).
Ketamine Indication, Dose, and Duration
The primary indications for CI ketamine were sedation (n = 170, 44%), analgesia (n = 115, 29%), and
analgosedation (when used for both analgesia and
sedation) (n = 72, 20%). Other indications included
status epilepticus (n = 14. 3.6%), bronchodilation
(n = 10, 2.6%), substance withdrawal (n = 5 1.3%),
suicidality/antidepressant (n = 1, 0.3%), increased
intracranial pressure (n = 1, 0.3%), and unknown
(n = 2, 0.5%) (Fig. 1, Supplemental Digital Content,
http://links.lww.com/CCX/A910). Ketamine was
used for pain most commonly in the surgical and
trauma ICU patient population, whereas it was used
for sedation and analgosedation mostly in the medical ICU population. Ketamine was more commonly
used as an adjunctive (n = 247, 69%) rather than
standalone agent (n = 110, 31%). The reason ketamine
was chosen could not be explained by any allergies,
intolerances, or clinical failure of traditional sedative
agents as the majority (n = 365, 93.6%) reported this
information was unavailable. At baseline, (n = 265,
75%) of patients were on a CI analgesic or sedative,
(n = 169, 48.1%) were on adjunctive nonopioid analgesics and sedatives, and (n = 11, 3.1%) had an epidural. Not all patients were on opioids (opioid use:
58.7% infusions, 25.1% scheduled intermittent doses,
79.8% as needed doses). Additional information on
baseline analgesic, sedative, and antipsychotic use
can be found in the Supplemental Digital Content
(Table S7, http://links.lww.com/CCX/A910).
February 2022 • Volume 4 • Number 2
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TABLE 1.

Baseline Demographics for Patients
Receiving Continuous Infusion Ketamine
(n = 390)
Demographics

Value

Weight, kg, mean ± sd (n = 313)

90.8 ± 27.7

Height, inches, mean ± sd (n = 260)

67.1 ± 4.4
318 (81.5)

Hispanic

26 (6.7)

Other/not reported

46 (11.8)

Race, n (%)
White
Black/African American
Other
Unknown

Continuous Infusion Ketamine Dose
and Administration (n = 390)
Dose Information

Value

Loading dose
Dose, mg/kg, median (IQR),
   n = 99

0.9 (0.4–1.0)

Weight, kg, median (IQR)

Ethnicity, n (%)
Non-Hispanic

TABLE 2.

244 (62.6)
64 (16.4)
7 (1.7)
75 (19.2)

Primary ICU type, n (%)
Medical

138 (35.3)

Surgical

91 (23.3)

Trauma

69 (17.7)

Cardiovascular

36 (9.2)

Neuroscience

29 (7.4)

Combined medical/surgical

17 (4.4)

82.7 (70.0–101.1)

Weight used, n (%)
  Actual

80 (80.8)

  Estimated

12 (12.1)

  Ideal

4 (4.0)

  Adjusted

3 (3.0)

Continuous infusion
Initial units, n (%)
  µg/kg/min

234 (60.0)

  mg/kg/hr

132 (33.9)

  mg/hr

24 (6.1)

Initial dose , median (IQR)
a

  Overall

0.2 (0.1–0.5)

  Analgesia

0.15 (0.09–0.3)

  Analgosedation

0.2 (0.12–0.3)

  Sedation

0.3 (0.12–0.5)

  Alcohol withdrawal

1.2 (1.1–1.25)
0.5 (0.08–0.9)

Burn

6 (1.5)

  Bronchodilation

Post-anesthesia

2 (0.5)

  Status epilepticus

Pediatric

1 (0.3)

Weight, kg, median (IQR), n = 366

Transplant

1 (0.3)

Weight used, n (%)

Hospital location at time of ketamine
initiation, n (%)
ICU
Emergency department

0.55 (0.3–1)

  Actual
362 (92.8)
17 (4.4)

300 (82.0)

  Ideal

38 (10.4)

  Estimated

18 (4.9)

  Adjusted

10 (2.7)

Progressive care/step-down

5 (1.3)

Operating room

5 (1.3)

Ketamine—titratable CI, n (%)

Post-anesthesia care unit

1 (0.3)

   Initial rate, dose, median (IQR)

Mechanical ventilation, n (%)

310 (79.5)

Ketamine initiated prior
to intubation

27 (8.7)

Ketamine discontinued after
extubation

47 (15.2)

The CI ketamine dose, dose units, and duration varied
and are found in Table 2. Only 25% of patients received
an initial bolus dose and the majority received weightbased CI doses in either µg/kg/min (60.0%) or mg/
kg/hr (33.9%) with actual body weight used in 80.8%
Critical Care Explorations

81.6 (68.0–98.5)

Ketamine titratable dose
228 (58.5)

   µg/kg/min (n = 176)

2.5 (1.4–5.0)

   mg/kg/hr (n = 41)

0.2 (0.1–0.5)

   mg/hr (n = 9)
   Unknown (n = 2)

10.0 (10.0–25.0)
—b

   Dose increments, median
   (IQR), n = 228
   µg/kg/min (n = 67)
   mg/kg/hr (n = 39)
   mg/hr (n = 8)

1 (1–5)
0.1 (0.1–0.2)
5 (5–20)
(Continued )

www.ccejournal.org
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TABLE 2. (Continued ).

Continuous Infusion Ketamine Dose
and Administration (n = 390)
—b

   Unknown (n = 114)
  Titration endpoints,
   n (%), n = 228
   Sedation score
   Pain score

128 (56.1)
56 (24.6)

   Burst suppression/seizures

3 (1.3)

   Incentive spirometry

2 (0.9)

   Wheezing

1 (0.4)

   Blood pressure

1 (0.4)

   Unknown

55 (24.1)

Ketamine fixed dose
Ketamine—fixed-rate CI, n (%)

162 (41.5)

   Initial rate, dose, median (IQR)

p = 0.781) in the 4 hours before and 4 hours after CI
ketamine. During the initial 4 hours of CI ketamine
hypertension, hypotension, tachycardia, and bradycardia occurred in 24.0% (n = 53), 23.5% (n = 52),
19.5% (n = 43), and 2.3% (n = 5) of patients, respectively. In the next 5–24 hours, there was a significant
increase in the incidence of hypertension (37.6%,
n = 83), which persisted at 25–48 hours (40.3%;
n = 89; p < 0.001). However, there was no difference
in the incidence of hypotension, tachycardia, or bradycardia at 5–24 hours (31.2%, 25.3%, and 4.5%, respectively) or at 25–48 hours (24.4%, 22.6%, and
3.2%, respectively). There was no indication that ketamine increased the risk for cardiac abnormalities
(Supplemental Digital Content, Table 9, http://links.
lww.com/CCX/A910).

   µg/kg/min (n = 57)

3.0 (1.8–5.5)

Additional Adverse Effects

   mg/kg/hr (n = 91)

0.5 (0.2–1.0)

Adverse effects potentially associated with CI ketamine during the initial 7 days were evaluated in 381
patients and are described in Table 3. Increased secretions or suctioning were most commonly identified in
53 patients (13.9%), of which 39 (10.2%) were within
the first 24 hours. Anticholinergic agents were initiated
in 10 (2.6%) and mucolytics in two patients (0.5%).
Emergence reactions at CI ketamine discontinuation
were reported in 20 patients (5.1%). Additional dissociative effects were reported in 10 patients (2.6%) during the initial 7 days; however, the remaining adverse
effects were less than 2%. Twenty-two patients (5.7%)
required discontinuation of CI ketamine due to adverse effects with agitation, dissociative effects, or hemodynamic changes being the most common.

   mg/hr (n = 14)

25.0 (25.0–33.0)

CI = continuous infusion, IQR = interquartile range.
a
All doses converted to mg/kg/hr.
b
Unable to determine value.

of patients. After converting the units to mg/kg/hr,
the median initial and discontinuation rates were 0.2
(0.1–0.5) and 0.3 (0.1–0.6), respectively. Median starting doses were greater than or equal to 0.5 mg/kg/hr
when used for alcohol withdrawal, bronchodilation, or
status epilepticus and less than 0.5 mg/kg/hr when use
for pain and agitation. Ketamine infusions were given
for a median duration of 1.6 days (0.6–2.9 d). A fixedrate strategy was used more than a titratable CI (58.5%
vs 41.5%). Additional data on daily ketamine cumulative, minimum, and maximum doses and volume
infused are available in Supplemental Digital Content
(Table S8, http://links.lww.com/CCX/A910).
Hemodynamic Changes
Hemodynamic changes before and after CI ketamine
were evaluated in 254 patients and were variable. There
were no significant differences between median SBP
(113.8 mm Hg [100.5–132.5 mm Hg] vs 114.5 mm Hg
[102.1–131.0 mm Hg]; p = 0.514), MAP (76 mm Hg
[68–88.1 mm Hg] vs 77.5 mm Hg [69.0–86.6 mm
Hg]; p = 0.237), and HR (94.3 beats/min [79.5–110.3
beats/min] vs 94.3 beats/min [79.5–110.0 beats/min];
6     www.ccejournal.org

Pain
In the 24 hours prior to, the first 0–24 hours, and
the 25–48 hours of CI ketamine, pain scores were
recorded in 285 (85%), 293 (87%), and 178 (90%)
patients a median of 10 (5–18), 11 (6–20), and 12
(6–20) times (p = 0.08), respectively. Goal pain scores
were known in 50.1% of patients. There was a statistically significant increase in the proportion of time
spent within goal pain score range after CI ketamine
initiation (24 hr prior: 68.9% [66.7–72.6%], 0–24 hr:
78.6% [74.3–82.5%], 25–48 hr: 80.3% [74.6–84.3%];
p < 0.001) (Fig. 2, Supplemental Digital Content,
http://links.lww.com/CCX/A910).
February 2022 • Volume 4 • Number 2
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TABLE 3.

Adverse Effects During Continuous Infusion Ketamine Administration
AE, n (%)

First 24 hr
(n = 381)

25–48 hr
(n = 221)

Day 3
(n = 133)

Day 4
(n = 78)

Day 5
(n = 60)

Day 6
(n = 41)

Day 7
(n = 30)

39 (10.4)

19 (8.6)

12 (9.0)

4 (5.1)

4 (6.7)

4 (9.8)

1 (3.3)

1 (0.3)

—

—

—

—

—

—

Increased secretions or suctioning
Yes

Medications started to control secretions
Atropine

a

Glycopyrrolate

2 (0.5)

1 (0.5)

—

—

1 (1.7)

—

—

Scopolamine

3 (0.8)

—

—

—

1 (1.7)

—

1 (3.3)

N-acetylcysteine

1 (0.3)

1 (0.5)

—

—

—

—

—

1 (0.3)

—

—

—

—

—

—

Seizure
Hypertonia

1 (0.3)

—

—

—

—

—

—

Allergic reaction

1 (0.3)

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

2 (1.5)b

1 (1.3)

1 (1.7)

1 (2.4)

—

Injection site reaction
Additional AE reported
Anxiety
Agitation

5 (1.3)

—

1 (0.8)

2 (2.6)

—

—

1 (3.3)

Dissociative effects

6 (1.6)

1 (0.5)

2 (1.5) b

3 (3.8)

—

1 (2.4)

3 (10.0)

Self-extubation

1 (0.3)

—

—

—

—

—

—

Oversedation

1 (0.3)

—

—

—

—

—

—

Somnolence

2 (0.5)

—

—

—

—

—

—

Nystagmus

2 (0.5)

—

—

—

—

—

—

Vision changes

1 (0.3)

1 (0.5)

1 (0.8)

—

—

—

—

Itching

1 (0.3)

—

—

—

—

—

—

Wheezing

1 (0.3)

—

—

—

—

—

—

14 (3.7)

3 (1.4)

1 (0.8)

2 (2.3)

1 (2.4)

1 (3.3)

Ketamine discontinued due to an AE
  Yes

-

AE = adverse effect.
a
Two were on anticholinergics at baseline and three had no documentation of increased secretions/suctioning.
b
One patient experiencing anxiety and dissociative effects also used medical marijuana at the time these effects occurred.
Dashes indicate occurrence rate = 0%.

Sedation

Analgesic, Sedative, and Antipsychotic Use

In the 24 hours prior to, the first 0–24 hours, and the
25–48 hours of CI ketamine, sedation scores were
recorded in 278 (80%), 304 (87%), and 182 (88%)
patients a median of 7 (4–13), 8 (4–16), and 9 (5–14)
times (p = 0.045), respectively. Goal sedation scores
were known in 62.5% of patients. There was a statistically significant increase in the proportion of time
spent within goal sedation score range after CI ketamine initiation (24 hr prior: 57.1% [52.5–60.0%], 0–24
hr: 64.1% [60.7–67.2%], 25–48 hr: 68.9% [65.5–79.5%];
p < 0.001) (Fig. 2, Supplemental Digital Content, http://
links.lww.com/CCX/A910).

Analgesic and sedative requirements were found to
be significantly reduced after the addition of CI ketamine. Median IV morphine equivalents decreased
from 120 mg (25–400 mg) in the 24 hours prior to ketamine to 118 mg (10–363 mg) in the first 0–24 hours
of the infusion and 80 mg (5–328 mg) in the 25–48
hours of the infusion (p < 0.005) (Fig. 3, Supplemental
Digital Content, http://links.lww.com/CCX/A910).
Median midazolam equivalents decreased from 11 mg
(4–67 mg) in the 24 hours prior to ketamine to 6 mg
(0–68 mg) in the first 0–24 hours of the infusion and
3 mg (0–57 mg) in the 25–48 hours of the infusion

Critical Care Explorations
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(p < 0.001). Median propofol dose decreased from
942 mg (223–4,018 mg), to 160 mg (0–2,776 mg), and
to 0 mg (0–1,859 mg) in the 24 hours prior to ketamine, the 0–24 hours of the infusion, and in the 25–48
hours of the infusion, respectively (p < 0.001). Median
dexmedetomidine dose decreased from 1,025 µg (276–
1,925 µg) in the 24 hours prior to ketamine to 285 µg
(0–1,283 µg) in the first 0–24 hours of the infusion
and 0 µg (0–826 µg) in the 25–48 hours of the infusion (p < 0.001) (Fig. 4, Supplemental Digital Content,
http://links.lww.com/CCX/A910). Antipsychotic use
was found in 44 of 351 patients (12.5%) at the time of
ketamine initiation. This did not significantly change
after the addition of CI ketamine as the proportion of
patients on antipsychotics in the first 0–24, 25–48, and
49–72 hours was 12.4% (43/346), 12.7% (26/205), and
13.0% (16/123), respectively (p > 0.99). Antipsychotic
use beyond 72 hours was not assessed as too few
patients remained on ketamine.
Delirium
In patients able to be assessed for delirium, 110 (45%),
115 (46%), and 59 (41%) had a delirium screening
performed in the 24 hours prior to, the first 0–24
hours, and 25–48 hours of CI ketamine, respectively.
There was no difference in proportion of time spent
positive for delirium after ketamine initiation (24 hr
prior: 43.0% [17.0–47.0%], 0–24 hr: 39.5% [27.0–
43.8%], 25–48 hr: 0% [0–43.7%]; p = 0.233) (Fig. 5,
Supplemental Digital Content, http://links.lww.com/
CCX/A910). Few patients remained on CI ketamine
beyond 72 hours; therefore, proportion of patients
positive for delirium could only be evaluated during
this time frame. There was a total of 228, 266, 121,
and 69 delirium screenings performed in the 24 hours
prior to, the first 0–24, 25–48, and 49–72 hours of CI
ketamine. The proportion of screenings positive for
delirium was not significantly different across these
time frames 45.2% (n = 103), 35.7% (n = 95), 40.5%
(n = 49), and 37.7% (n = 26), respectively (p = 0.191).
However, there was a significant reduction in the proportion of positive delirium screenings when comparing the 24 hours prior with the first 0–24 hours of CI
ketamine (45.2% vs 35.7%; p = 0.041). This did not remain significant when the 24 hours prior to CI ketamine was compared with the other timeframes: 25–48
hours (45.2% vs 40.5%; p = 0.468), 49–72 hours (45.2%
vs 37.7%; p = 0.336).
8     www.ccejournal.org

Patient Outcomes
Patient outcomes are consistent with a moderate to severely ill patient population with lengths of ICU and
hospital stay on average greater than 1 and 2 weeks, respectively. The majority of patients survived and were
discharged home (Table 4).

DISCUSSION
This large, multicenter study demonstrates widespread
use of CI ketamine in many types of ICUs and highlights substantial variability in indication and dose but
a clinically acceptable safety profile. After ketamine
initiation, patients spent more time in goal pain and
sedation score range with reduced exposure to other
analgesics and sedatives, without increased delirium.
These data are consistent with smaller studies evaluating ketamine as an analgesic and analgosedative agent
in an ICU setting (4, 10, 16).
We identified practice variations in CI ketamine
dose. Infusion dose units were not consistent but
most were ordered in µg/kg/min and were titratable.
However, many of these orders (24%) were not written with specific titration parameters, which is a safety
concern not compliant with The Joint Commission
on Accreditation of Healthcare Organizations

TABLE 4.

Clinical Outcomes Associated With
Continuous Infusion Ketamine
Clinical Outcome

Value

Length of stay, d, median (IQR)
9.9 (4.3–18.7)

ICU (n = 380)

15.5 (7.4–27.5)

Hospital (n = 381)
Duration of mechanical ventilation,
d, median (IQR), n = 310

7.1 (2.9–15.7)

Mortality, n = 348, n (%)
ICU

69 (19.8)

Hospital

73 (21.0)

Discharge disposition, n = 275, n (%)
Home/correctional facility

149 (54.2)

Skilled nursing facility/long-term
care/rehabilitation center

110 (40.0)

Transfer to another hospital

8 (2.9)

Hospice

8 (2.9)

IQR = interquartile range.
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recommendations (17). Our data also suggest lack of
ketamine weaning before discontinuation since median discontinuation doses were higher than starting
doses. A high percentage of patients also remained on
ketamine after extubation, which is plausible as ketamine does not impair respiratory drive at subanesthetic doses (1).
Ketamine is a sympathomimetic and negative inotrope known to inhibit catecholamine reuptake and
monoamine transport and block L-type calcium channels (2, 3). Hypertension (5–25%) and tachycardia
(2–62%) have been commonly reported in other trials (12). We found similar rates with hypertension
occurring in 24% and tachycardia in 19.5% of patients.
Hypertension was more common in the first 4 hours
of the infusion compared with 5–24 and 48 hours.
Hypotension has been reported in 16.3% of patients
and cardiovascular collapse may occur in catecholamine-depleted patients (12, 18, 19). We found hypotension to be common, occurring in 23.5% of patients
with a trend toward an increase in incidence during
the 5–24 hours of the infusion. A high percentage of
our patient population received vasopressors, but we
found the hemodynamic effects remained the same regardless of vasopressor administration. Interestingly,
median SBP, MAP, and HR in the 4 hours prior to ketamine use compared with the first 4 hours of the infusion remained unchanged. It also does not appear
these hemodynamic changes increased the risk for
cardiac abnormalities such as arrhythmias. The reasons for why we found such a wide variability in hemodynamic effects are unknown but possibly related
to our study definitions, concomitant medication use,
or confounding factors related to critical illness.
Common noncardiovascular adverse effects were
secretions and need for anticholinergic or mucolytic medications (13.9% and 3.0%, respectively) and
emergence reactions (5%). We found a 5.7% discontinuation rate due to adverse effects, mostly due to agitation/dissociative effects and hemodynamic changes
that did not appear to relate to length of time on ketamine since most discontinuations occurred within the
first 24 hours. This is similar to a rate of 7.7% reported
in a previous study (20).
Pain and sedation were the most common indications for CI ketamine. Current consensus guidelines
from the American Academy of Pain Medicine endorse
ketamine use for the treatment of acute pain in certain
Critical Care Explorations

patient populations, however, specific recommendations on its use as a CI in the ICU are lacking (21).
Ketamine has been shown to reduce opioid requirements in both trauma and surgical ICU patients (4, 10).
A recent meta-analysis evaluating adjunctive analgesic
use in the critically ill found ketamine use was associated with reduced opioid requirements by a mean
difference of 36.81 mg (95% CI, 27.32–46.30 mg) of
oral morphine equivalents in 24 hours (22). Within 48
hours of ketamine initiation, we were able to show a
median difference of 120 mg oral (40 mg IV) morphine
equivalents, as well as improved time in goal pain score
range. Reducing opioid requirements during ICU stay
may have significant downstream effects as 12–73% of
ICU survivors report chronic pain with a similar proportion being prescribed opioids at discharge (23–25).
Additionally, it has been shown that 4–19% will become chronic opioid users irrespective of opioid use
prior to admission (23–25). It is unknown if high doses
or prolonged infusions of opioids in the ICU are associated with chronic opioid use but those receiving
opioids during a hospitalization are twice as likely to
have opioids prescribed at discharge than those not
receiving opioids (26). In addition to transitioning to
chronic use, other risks of opioids include nausea and
vomiting, constipation, ileus, immunosuppression,
and delirium. Therefore, use of nonopioid pain medications, such as ketamine, that can reduce opioid exposure, may reduce these risks.
Ketamine has been evaluated as an analgosedative
agent in the ICU and its reported effects on sedation
practices are variable. Several small, retrospective,
observational studies have demonstrated that ketamine may reduce exposure to opioids and sedatives
(4, 16, 20, 27–29) and improve time spent in goal sedation score range (20, 29). A recent meta-analysis included 15 studies (12 observational, three randomized)
evaluating the use of CI ketamine for sedation in 892
mechanically ventilated patients (12). Doses and dose
strategies (fixed dose vs titration) were inconsistent
and ranged from 0.05 to 4.9 mg/kg/hr. Ketamine use
was associated with reduced infusion rates of propofol (mean difference, –699 µg/min [95% CI, –1,168 to
–230 µg/min]; p = 0.003) but failed to demonstrate any
effect on fentanyl (mean difference, –21.5 µg/hr [95%
CI, –48.2 to 5.1 µg/hr]; p = 0.11) or midazolam (mean
difference, –0.3 mg/hr [95% CI, –0.95 to 0.35 mg/hr];
p = 0.37) requirements. Ketamine did not improve the
www.ccejournal.org
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ability to achieve goal sedation (odds ratio, 0.51; 95%
CI, 0.14–1.88; p = 0.31). However, they looked at the
number of measurements at goal sedation that may
be dependent upon the frequency or timing of assessments made, or the number of patients at goal sedation that may be a static measure at a single moment
in time, rather than evaluating the effects over time. In
contrast, our study found improvements in target sedation according to proportion of time spent in goal sedation score range measured throughout the treatment
period. This is a more clinically meaningful endpoint
as it captures the magnitude of effect over a prolonged
time frame compared with a single point in time.
The impact of ketamine on ICU delirium is unknown. It may potentially mitigate or prevent delirium
by reducing neuroexcitation and inflammatory cytokines or by reducing exposure to known deliriogenic
medications. However, it may also increase the risk
for delirium due to its known psychotomimetic effects
(30–34). There are mixed findings related to ketamine
and delirium in the literature. One study demonstrated
CI ketamine can decrease the duration of delirium independent of reducing exposure to opioid and sedative
infusions and another found no difference in number
of days alive without delirium or coma, although ketamine treated patients had a higher percentage with
coma, which likely confounded detection of delirium
(30, 31). These data, despite limitations, indicate ketamine does not appear to increase the risk for delirium,
which is similar to our findings. It also highlights the
low frequency at which delirium is assessed, which was
also demonstrated in our study. On the other hand, a
more recent analysis by Wu et al (34) did find an association between ketamine use and ICU delirium using
a more rigorous multivariable, time-dependent model
in 925 critically ill patients. The median dose of ketamine used was 0.5 mg/kg/hr, which is higher than average doses seen in other studies including this report.
Further data are needed to explore the dose response
effect of ketamine on ICU delirium.
Our study is novel by evaluating ketamine use
across multiple geographically diverse institutions.
We included a large sample size of patients, evaluated
endpoints relevant to clinical practice, and had clear
definitions to limit variability in data collection. There
are several limitations mainly due to the retrospective
design with lack of a comparison group and potential
missing or incomplete data. The study period was from
10     www.ccejournal.org

2014 to 2017 and the majority of patients included were
from five of the 25 participating institutions. Usage patterns may have changed since this time frame and the
results are only representative of a sample of institutions across the country. Additionally, not all patients
who received ketamine during this time frame were
included. We did include the most recent patients receiving ketamine, but there is still the potential for selection bias. Having multiple data collectors may have
raised inconsistencies in data collection. However, we
attempted to ensure data integrity prior to study initiation by having a standardized data collection tool,
data dictionary, extensive testing and refinement by
the study group and participating site investigators,
and conference calls to field questions and provide
consensus on how certain data points should be collected. As many confounders are likely present in critically ill patients, the hemodynamic effects seen with CI
ketamine can only be used to describe the patient population receiving this therapy. The rationale for adding ketamine to current pain and sedation regimens
were not consistently documented; therefore, we can
only assume that it was due to failure to achieve goal
pain and sedation scores in those already receiving
conventional therapy. The goal levels of pain and sedation were not known in a large percentage of patients
likely due to poor chart documentation. Therefore, we
had to make assumptions that could limit generalizability. Not all patients received analgesia; therefore,
our results might not apply to patients receiving an adequate multimodal approach to pain. We found very
few patients with documented delirium screenings
and it is also unknown if the ICU liberation (A to F)
bundle, an intervention known to reduce the duration
of delirium, was used in these patients. Therefore, any
associations on the risk of delirium with CI ketamine
cannot be concluded from these data. Since we did not
have a comparator group, it is also possible that time
played a role in reducing doses of analgesics and sedatives as patients may have been improving clinically.
Regardless, proportion of time spent in goal pain/sedation score range improved after the addition of CI ketamine. Including a group of diverse institutions adds
strength, but it also limits the applicability due to heterogeneity in pain and sedation practices. We did not
perform an economic analysis or compare ketamine
to other sedatives on time spent in the ICU or on the
ventilator, however, ketamine is relatively inexpensive
February 2022 • Volume 4 • Number 2
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compared with other agents. Despite these limitations,
this study adds to the body of literature demonstrating the benefits of CI ketamine and clinicians could
consider this therapy to reduce exposure to opioids
and improve proportion of time in goal pain/sedation
score range for critically ill patients.

CONCLUSIONS
In the largest study to date exploring the effects of realworld CI ketamine use in the ICU, a greater proportion of time was spent in goal pain and sedation score
range with a reduction in exposure to other sedatives
and analgesics in the short time frame after it’s initiation. This is in addition to an acceptable safety profile and no observed increase in time spent positive
for delirium. Ketamine can be considered in critically
ill patients, especially in those failing traditional analgesic and sedative agents. It can be used to decrease
exposure to opioids and known deliriogenic sedatives
such as benzodiazepines, but larger, randomized controlled trials for its proposed indications are necessary
to guide appropriate use and determine its economic
value in reducing time in the ICU and on the ventilator.
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